Total trials
1,161
Active
244
Phase 3
318
Total enrollment
416,812
Pipeline matrix
Showing 40 of 163 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Venetoclax | — | 57 | |||||
| Azacitidine | — | — | 13 | ||||
| Upadacitinib | — | 55 | |||||
| Risankizumab | — | 57 | |||||
| Telisotuzumab Adizutecan | — | — | 13 | ||||
| Bevacizumab | — | — | — | 15 | |||
| Budigalimab | — | — | — | 15 | |||
| Carboplatin | — | — | — | 28 | |||
| Dexamethasone | — | — | — | 24 | |||
| Lutikizumab | — | — | — | — | 8 | ||
| Etentamig | — | — | — | 7 | |||
| Atogepant | — | — | 12 | ||||
| Daratumumab | — | — | — | 7 | |||
| Livmoniplimab | — | — | — | 6 | |||
| Pomalidomide | — | — | — | 7 | |||
| Cisplatin | — | — | — | 7 | |||
| Lenalidomide | — | — | — | 6 | |||
| Fluorouracil | — | — | — | — | 6 | ||
| Adalimumab | — | 65 | |||||
| Telisotuzumab Vedotin | — | — | 7 | ||||
| Ubrogepant | — | — | — | 6 | |||
| Pemetrexed | — | — | — | 7 | |||
| Ruxolitinib | — | — | — | 6 | |||
| Obinutuzumab | — | — | — | 5 | |||
| Docetaxel | — | — | — | 5 | |||
| Carfilzomib | — | — | — | 4 | |||
| Oxaliplatin | — | — | — | — | 4 | ||
| Osimertinib | — | — | — | — | 4 | ||
| Standard of Care | — | — | — | — | 4 | ||
| Topical Steroid | — | — | — | — | 3 | ||
| ABBV-RGX-314 Dose 1 | — | — | — | — | 3 | ||
| ABBV-RGX-314 Dose 2 | — | — | — | — | 3 | ||
| Navitoclax | — | — | 10 | ||||
| ABBV-706 | — | — | 4 | ||||
| risankizumab SC | — | — | — | — | 6 | ||
| Bortezomib | — | — | — | 5 | |||
| Irinotecan | — | — | — | 4 | |||
| Pembrolizumab | — | — | — | 3 | |||
| Surabgene Lomparvovec | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | 2 |
123 more active programs hidden
Next readouts
- 2017-10-27
- 2020-06-22
- 2020-10-08
- 2021-02-16
- 2021-12-01
- 2023-09-06
- 2024-02-07
- 2025-01-29
- 2025-04-28
- 2025-07-07
Top conditions
- Rheumatoid Arthritis56
- Psoriasis48
- Crohn's Disease44
- Healthy Volunteer36
- Healthy Volunteers36
- Chronic Hepatitis C35
- Psoriatic Arthritis27
- Ulcerative Colitis26
Frequently asked questions about AbbVie
- How many clinical trials does AbbVie have on ClinicalTrials.gov?
- AbbVie is listed as the lead sponsor on 1,161 clinical trials in ClinicalTrials.gov, 244 of which are currently active (recruiting, enrolling, or ongoing).
- How many of AbbVie's trials are in Phase 3?
- 318 of AbbVie's trials are in Phase 3, spread across 163 active drug programs.
- What therapeutic areas does AbbVie focus on?
- AbbVie's most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Healthy Volunteer, Healthy Volunteers.
- When are AbbVie's next clinical trial readouts?
- AbbVie has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate”, expected around 2017-10-27.